Fatigue News and Research

RSS

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

While lab tests and imaging can sometimes help diagnose juvenile idiopathic arthritis (JIA), a physical examination and thorough patient history are the most valuable tools in identifying this disease. According to a new literature review from the Journal of the American Academy of Orthopaedic Surgeons (JAAOS), the rate of false positives in laboratory evaluations and imaging studies meant to screen for juvenile arthritis makes their value limited.

3 Mar 2011

Health care needs to look to aviation industry to improve safety

In a commentary published today in the Journal of the American Medical Association, a leading patient safety expert argues that failure to integrate new electronic equipment in modern hospital operating rooms and intensive care units results in diagnostic mistakes, failures to identify deteriorating patients, communication errors and inefficient work.

2 Mar 2011

Recent ACGME limits aimed to enhance patient safety may compromise quality of doctors' training

Recent Accreditation Council for Graduate Medical Education limits aimed to enhance patient safety may compromise the quality of doctors' training, according to a study by Mayo Clinic researchers published in the March issue of Mayo Clinic Proceedings.

2 Mar 2011

Genetic switch increases blood vessels in skeletal muscle of non-exercising mice

Many people suffer from a devastating condition known as critical limb ischemia (CLI) that can lead to muscle wasting and even amputation. The disease is linked to the blockage of blood flow to the skeletal muscle and current treatment options include rehabilitative exercise and surgical bypass of blood vessels. New preclinical research suggests there may be a way to restore blood supply in skeletal muscle without traditional intervention.

2 Mar 2011

High blood pressure medications useful even in those without hypertension: Study

Researchers have studied existing evidence to suggest that people who have had a stroke or a heart attack might benefit from taking blood pressure medications, even if they do not have high blood. They noted that for every 1,000 people taking the drugs in clinical trials, on average 15 fewer died from heart disease than when the patients got dummy treatment. The study however could not explain the cause for this benefit. The study, which was funded by Tulane University and the National Institutes of Health, was published in the March 2 issue of the Journal of the American Medical Association.

1 Mar 2011

U-M's SIVQ software-tool can pinpoint cell and tissue samples more accurately

Ulysses Balis, M.D., clicks a mouse to identify a helicopter in a satellite photo of Baghdad, Iraq. With another click, an algorithm that he and his team designed picks out three more choppers without highlighting any of the buildings, streets, trees or cars.

1 Mar 2011

Endo fourth quarter total revenues increase 31% to $511 million

Endo Pharmaceuticals today reported financial results for the fourth quarter 2010.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

A new analysis has found that supplementing the diet with fish oil may prevent muscle and weight loss that commonly occurs in cancer patients who undergo chemotherapy. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that fish oil may help combat cancer-related malnutrition.

28 Feb 2011

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that encouraging preliminary results of a Phase 2 trial of ganetespib as a single agent in non-small cell lung cancer were presented at the International Association for the Study of Lung Cancer 11th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.

27 Feb 2011

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Hashimoto's thyroiditis, an inflammatory disorder of the thyroid, is the most common cause of hypothyroidism, but a study has suggested that even when thyroid function is normal, HT may increase symptoms and decrease quality of life, as described in an article in Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc.

27 Feb 2011

Lyme’s disease and chronic fatigue syndrome biomarkers found

A new study shows that spinal fluid can be used to detect proteins that help distinguish patients with Lyme disease from those with chronic fatigue syndrome.

27 Feb 2011

Ballerinas need to know dangers of excessive weight loss and overexercise

With actress Natalie Portman in Oscar contention, the movie "Black Swan" has taken center stage. So have concerns surrounding the dramatic weight loss Portman underwent for the role. Her depiction of a dangerously thin ballerina sheds light on a potential downside of this art form.

25 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

Study findings support therapeutic approach for common form of MS

In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches - but they're on opposite sides of the spectrum. Researchers at Wayne State University's School of Medicine, however, have reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue.

24 Feb 2011

New research: Spinal fluid proteins can differentiate nPTLS from Chronic Fatigue Syndrome

Patients who suffer from Neurologic Post Treatment Lyme disease and those with the Chronic Fatigue Syndrome report similar symptoms. However unique proteins discovered in spinal fluid can distinguish those two groups from one another and also from people in normal health, according to new research conducted by a team led by Steven E. Schutzer, MD, of the University of Medicine and Dentistry of New Jersey - New Jersey Medical School, and Richard D. Smith, Ph.D., of Pacific Northwest National Laboratory.

24 Feb 2011

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

Amgen today announced the publication of results from a pivotal Phase 3 study of 1,776 advanced cancer patients with different types of solid tumors or multiple myeloma, which compared XGEVA to Zometa in preventing skeletal-related events.

23 Feb 2011

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

Fatigue News and Research

Early diagnosis of juvenile idiopathic arthritis critical to avoid disability, deformity

Health care needs to look to aviation industry to improve safety

Recent ACGME limits aimed to enhance patient safety may compromise quality of doctors' training

Genetic switch increases blood vessels in skeletal muscle of non-exercising mice

High blood pressure medications useful even in those without hypertension: Study

U-M's SIVQ software-tool can pinpoint cell and tissue samples more accurately

Endo fourth quarter total revenues increase 31% to $511 million

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Study: Fish oil may prevent muscle and weight loss in cancer patients during chemotherapy

Encouraging preliminary results from Synta's ganetespib Phase 2 trial against non-small cell lung cancer

Study: HT may affect symptom load and quality of life unrelated to hypothyroidism

Lyme’s disease and chronic fatigue syndrome biomarkers found

Ballerinas need to know dangers of excessive weight loss and overexercise

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Study findings support therapeutic approach for common form of MS

New research: Spinal fluid proteins can differentiate nPTLS from Chronic Fatigue Syndrome

Amgen announces publication of XGEVA Phase 3 study results against solid tumors in Journal of Clinical Oncology

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News